Sam's Club Pharmacy vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Walmart-owned warehouse club pharmacy with 500+ locations; bulk purchasing enables discounted $4/$10 generics competing with Costco Pharmacy as part of Walmart's health services strategy.
About
Sam's Club Pharmacy is the pharmacy division operating within Sam's Club warehouse membership clubs, providing prescription filling, immunizations, health screenings, and specialty pharmacy services to Sam's Club members at competitive pricing leveraging Walmart's pharmaceutical purchasing scale. Part of Walmart Inc. (NYSE: WMT), Sam's Club Pharmacy operates more than 500 pharmacy locations inside Sam's Club warehouse clubs across the United States, offering members discounted prescription pricing as part of the Sam's Club membership value proposition.\n\nSam's Club Pharmacy's competitive advantage lies in Walmart's massive pharmaceutical purchasing power — the combined Walmart/Sam's Club pharmacy network is one of the largest in the US, enabling negotiated drug pricing that can undercut traditional retail pharmacies. Members access prescriptions at Sam's Club prices with convenient access during their warehouse shopping trips. The pharmacy offers $4/$10 generic prescription pricing for common medications, mail-order options, and immunization services.\n\nIn 2025, Sam's Club Pharmacy operates within Walmart's broader health strategy — Walmart Health (primary care clinics) and Walmart+ pharmacy benefits are being integrated to create a comprehensive health services ecosystem for Walmart and Sam's Club customers. The retail pharmacy market faces structural challenges from pharmacy benefit manager (PBM) reimbursement pressure that has forced independent and chain pharmacy closures. Sam's Club Pharmacy competes with Costco Pharmacy (similar warehouse model), CVS, Walgreens, and mail-order PBM pharmacies. The 2025 strategy focuses on expanding specialty pharmacy capabilities, integrating prescription benefits with Walmart+ membership, and growing immunization and preventive health services.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.